Current Rheumatology Reports最新文献_第10页

Neuromodulation as a Potential Disease-Modifying Therapy for Osteoarthritis. 将神经调节作为骨关节炎的一种潜在疾病调节疗法

IF 5.7 2区医学

Current Rheumatology Reports Pub Date : 2023-01-01 Epub Date: 2022-11-26 DOI: 10.1007/s11926-022-01094-2

Carlos J Cruz, L Savannah Dewberry, Kevin J Otto, Kyle D Allen

{"title":"Neuromodulation as a Potential Disease-Modifying Therapy for Osteoarthritis.","authors":"Carlos J Cruz, L Savannah Dewberry, Kevin J Otto, Kyle D Allen","doi":"10.1007/s11926-022-01094-2","DOIUrl":"10.1007/s11926-022-01094-2","url":null,"abstract":"Purpose of review: The following review discusses the therapeutic potential of targeting the autonomic nervous system (ANS) for osteoarthritis (OA) treatment and encourages the field to consider the candidacy of bioelectronic medicine as a novel OA treatment strategy.Recent findings: The study of OA pathogenesis has focused on changes occurring at the joint level. As such, treatments for OA have been aimed at the local joint environment, intending to resolve local inflammation and decrease pain. However, OA pathogenesis has shown to be more than joint wear and tear. Specifically, OA-related peripheral and central sensitization can prompt neuroplastic changes in the nervous system beyond the articular joint. These neuroplastic changes may alter physiologic systems, like the neuroimmune axis. In this way, OA and related comorbidities may share roots in the form of altered neuroimmune communication and autonomic dysfunction. ANS modulation may be able to modify OA pathogenesis or reduce the impact of OA comorbidities. Moreover, blocking chronic nociceptive drive from the joint may help to prevent maladaptive nervous system plasticity in OA.","PeriodicalId":10761,"journal":{"name":"Current Rheumatology Reports","volume":"25 1","pages":"1-11"},"PeriodicalIF":5.7,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11438129/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9561235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Neurosarcoidosis: Phenotypes, Approach to Diagnosis and Treatment. 神经结节病:表型，诊断和治疗方法。

IF 5 2区医学

Current Rheumatology Reports Pub Date : 2022-12-01 Epub Date: 2022-10-12 DOI: 10.1007/s11926-022-01089-z

Jeanne Gosselin, Chantal Roy-Hewitson, Sean S M Bullis, John C DeWitt, Bruno P Soares, Sidarth Dasari, Alana Nevares

{"title":"Neurosarcoidosis: Phenotypes, Approach to Diagnosis and Treatment.","authors":"Jeanne Gosselin, Chantal Roy-Hewitson, Sean S M Bullis, John C DeWitt, Bruno P Soares, Sidarth Dasari, Alana Nevares","doi":"10.1007/s11926-022-01089-z","DOIUrl":"https://doi.org/10.1007/s11926-022-01089-z","url":null,"abstract":"Purpose of review: The aim of this review is to provide an update of clinical presentation, diagnosis, differential diagnoses, and treatment according to recent evidence.Recent findings: Neurosarcoidosis remains a diagnosis of exclusion, with infectious and malignant etiologies recognized as important mimickers. Corticosteroids remain as first-line therapy. In recent years, however, studies have demonstrated the effectiveness of anti-tumor necrosis factor (anti-TNF) therapy in the treatment of neurosarcoidosis, leading to improved outcomes. Neurosarcoidosis is a granulomatous disease with protean manifestations that may affect any part of the central and peripheral nervous system. It has many mimickers, and potentially devastating complications necessitating long-term follow-up. Early initiation of treatment, particularly with anti-TNF therapy, may lead to better outcomes and fewer relapses. There is an unmet need for randomized controlled trials that provide robust data to guide therapy and the long-term management of neurosarcoidosis patients.","PeriodicalId":10761,"journal":{"name":"Current Rheumatology Reports","volume":"24 12","pages":"371-382"},"PeriodicalIF":5.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33500885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 6

T cell Repertoire Profiling and the Mechanism by which HLA-B27 Causes Ankylosing Spondylitis. T细胞库谱分析和HLA-B27引起强直性脊柱炎的机制。

IF 5 2区医学

Current Rheumatology Reports Pub Date : 2022-12-01 Epub Date: 2022-10-05 DOI: 10.1007/s11926-022-01090-6

Jose Garrido-Mesa, Matthew A Brown

{"title":"T cell Repertoire Profiling and the Mechanism by which HLA-B27 Causes Ankylosing Spondylitis.","authors":"Jose Garrido-Mesa, Matthew A Brown","doi":"10.1007/s11926-022-01090-6","DOIUrl":"https://doi.org/10.1007/s11926-022-01090-6","url":null,"abstract":"Purpose of review: Ankylosing spondylitis (AS) is strongly associated with the HLA-B27 gene. The canonical function of HLA-B27 is to present antigenic peptides to CD8 lymphocytes, leading to adaptive immune responses. The 'arthritogenic peptide' theory as to the mechanism by which HLA-B27 induces ankylosing spondylitis proposes that HLA-B27 presents peptides derived from exogenous sources such as bacteria to CD8 lymphocytes, which subsequently cross-react with antigens at the site of inflammation of the disease, causing inflammation. This review describes findings of studies in AS involving profiling of T cell expansions and discusses future research opportunities based on these findings.Recent findings: Consistent with this theory, there is an expanding body of data showing that expansion of a restricted pool of CD8 lymphocytes is found in most AS patients yet only in a small proportion of healthy HLA-B27 carriers. These exciting findings strongly support the theory that AS is driven by presentation of antigenic peptides to the adaptive immune system by HLA-B27. They point to new potential approaches to identify the exogenous and endogenous antigens involved and to potential therapies for the disease.","PeriodicalId":10761,"journal":{"name":"Current Rheumatology Reports","volume":"24 12","pages":"398-410"},"PeriodicalIF":5.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9666335/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33505092","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 13

Use of Imaging in Axial Spondyloarthritis for Diagnosis and Assessment of Disease Remission in the Year 2022. 2022年影像学在轴型脊柱炎诊断和疾病缓解评估中的应用

IF 5 2区医学

Current Rheumatology Reports Pub Date : 2022-12-01 Epub Date: 2022-10-15 DOI: 10.1007/s11926-022-01091-5

Ann-Sophie De Craemer, Zuzanna Łukasik, Philippe Carron

{"title":"Use of Imaging in Axial Spondyloarthritis for Diagnosis and Assessment of Disease Remission in the Year 2022.","authors":"Ann-Sophie De Craemer, Zuzanna Łukasik, Philippe Carron","doi":"10.1007/s11926-022-01091-5","DOIUrl":"https://doi.org/10.1007/s11926-022-01091-5","url":null,"abstract":"Medical imaging remains the cornerstone of diagnostics and follow-up of axial spondyloarthritis (axSpA) patients. With the lack of specific biomarkers allowing monitoring of disease activity and progression, clinicians refer to imaging modalities for accurate evaluation of the axSpA burden. Technological advances and increasing availability of modern imaging techniques such as MRI have enabled faster diagnosis of the disease, hence dramatically changed the diagnostic delay and improved the prognosis and functional outcomes for axSpA patients.Active sacroiliitis as visualized by MRI has been widely accepted as a diagnostic tool, and definitions of inflammatory and structural lesions within the axial skeleton have been developed. Recently, it has been acknowledged that bone marrow edema, suggestive of sacroiliitis, is a common finding among non-SpA patients, and could be attributed to mechanical loading or accumulate with age in healthy individuals. Therefore, it is crucial to distinguish between true pathological and concealing imaging findings, not only for diagnostic but also for disease remission purposes. New imaging modalities, aimed for in vivo visualization of specific molecular processes, could be employed to cross-validate findings from techniques used in daily clinical practice. This review critically evaluates the use of different imaging modalities for diagnosis and assessment of disease remission in axSpA in the year 2022.","PeriodicalId":10761,"journal":{"name":"Current Rheumatology Reports","volume":"24 12","pages":"383-397"},"PeriodicalIF":5.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33513228","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

At the Heart of Eosinophilic Granulomatosis with Polyangiitis: into Cardiac and Vascular Involvement. 嗜酸性肉芽肿病合并多血管炎的心脏:进入心脏和血管累及。

IF 5 2区医学

Current Rheumatology Reports Pub Date : 2022-11-01 Epub Date: 2022-10-04 DOI: 10.1007/s11926-022-01087-1

Milena Bond, Filippo Fagni, Michele Moretti, Federica Bello, Allyson Egan, Augusto Vaglio, Giacomo Emmi, Christian Dejaco

{"title":"At the Heart of Eosinophilic Granulomatosis with Polyangiitis: into Cardiac and Vascular Involvement.","authors":"Milena Bond, Filippo Fagni, Michele Moretti, Federica Bello, Allyson Egan, Augusto Vaglio, Giacomo Emmi, Christian Dejaco","doi":"10.1007/s11926-022-01087-1","DOIUrl":"https://doi.org/10.1007/s11926-022-01087-1","url":null,"abstract":"Purpose of review: To provide an overview of existing literature on pathogenetic and clinical aspects of cardiac and vascular involvement in eosinophilic granulomatosis with polyangiitis (EGPA).Recent findings: In EGPA, cardiac and vascular involvement are more common than previously thought. However, no international recommendations on the topic are available yet. Herein, we summarize the existing evidence on the topic and propose a diagnostic approach for cardiac involvement in EGPA. The prevalence of cardiovascular involvement in patients with EGPA varies greatly among published studies, ranging between 3.1-18.7% for occlusive arterial disease, 5.8-30% for venous thrombosis and 17-92% for heart involvement. Cardiac involvement in EGPA is associated with high mortality even though manifestations are heterogeneous. In principle, every anatomical structure of the heart can be involved, and EGPA-related heart disease may be completely asymptomatic at first. A careful diagnostic work-up for early detection and prompt treatment initiation is therefore required. While cardiac manifestations are more common in anti-neutrophil cytoplasmic antibodies (ANCA)-negative patients, arterial and venous thrombotic events are not linked to ANCA status but correlate closely with disease activity and accumulate at disease onset. Thrombotic events (mainly venous) are considerably more frequent in EGPA than in the general population contributing substantially to morbidity and highlighting the importance of developing specific prevention strategies for patients who are diagnosed with EGPA.","PeriodicalId":10761,"journal":{"name":"Current Rheumatology Reports","volume":"24 11","pages":"337-351"},"PeriodicalIF":5.0,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33488087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4

Spectrum of Large- and Medium-Vessel Vasculitis in Adults: Neoplastic, Infectious, Drug-Induced, Autoinflammatory, and Primary Immunodeficiency Diseases. 成人大血管和中血管炎谱：肿瘤性、感染性、药物诱发、自身炎症和原发性免疫缺陷疾病。

IF 5.7 2区医学

Current Rheumatology Reports Pub Date : 2022-10-01 Epub Date: 2022-08-03 DOI: 10.1007/s11926-022-01083-5

Fabian Lötscher, Roxana Pop, Pascal Seitz, Mike Recher, Luca Seitz

引用次数: 0

Inhibiting IL-17A and IL-17F in Rheumatic Disease: Therapeutics Help to Elucidate Disease Mechanisms. 抑制风湿病中的 IL-17A 和 IL-17F：治疗有助于阐明疾病机制

IF 5.7 2区医学

Current Rheumatology Reports Pub Date : 2022-10-01 Epub Date: 2022-07-21 DOI: 10.1007/s11926-022-01084-4

Hoi Ki Joshua Tam, Philip C Robinson, Peter Nash

{"title":"Inhibiting IL-17A and IL-17F in Rheumatic Disease: Therapeutics Help to Elucidate Disease Mechanisms.","authors":"Hoi Ki Joshua Tam, Philip C Robinson, Peter Nash","doi":"10.1007/s11926-022-01084-4","DOIUrl":"10.1007/s11926-022-01084-4","url":null,"abstract":"Purpose of review: Psoriatic arthritis and ankylosing spondylitis belong to a family of rheumatological diseases that lead to painful joint inflammation that impacts on patient function and quality of life. Recent studies have shown that the pro-inflammatory cytokine IL-17 is involved in the inflammatory joint changes in spondyloarthritides. We will review the pathophysiology of IL-17 and review the biological therapies targeting IL-17.Recent findings: IL-17 is produced and released from T cells and is dependent on multiple upstream cytokines, which include IL-23. There are six members of the IL-17 family that are secreted from multiple populations of T cells. The initial biologic medications have been developed against IL-17A, which is the best-studied member of this family. These medications appear to be effective in controlling joint inflammation, improving patient quality of life, and are generally well tolerated. More recently, medications have been developed that target both IL-17A and IL-17F. In addition, brodalumab, an antibody targeting the IL-17 receptor, has had a resurgence after initial concerns for an increased risk of suicide. IL-17 is an inflammatory cytokine that is critical in the pathobiology of axial spondyloarthritides. Recent biological therapies targeting IL-17A are effective and well tolerated in patients with axial spondyloarthritis. Specific targeting of the Il-17A/F heterodimer is also effective and provides another viable option in the clinician's armamentarium.","PeriodicalId":10761,"journal":{"name":"Current Rheumatology Reports","volume":"24 10","pages":"310-320"},"PeriodicalIF":5.7,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9470681/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40542091","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correction to: Detection and Monitoring of Interstitial Lung Disease in Patients with Systemic Sclerosis. 修正:系统性硬化症患者间质性肺疾病的检测和监测。

IF 5 2区医学

Current Rheumatology Reports Pub Date : 2022-10-01 DOI: 10.1007/s11926-022-01085-3

Surabhi Agarwal Khanna, John W Nance, Sally A Suliman

引用次数: 0

What to Know About Biopsy Sampling and Pathology in Vasculitis? 关于血管炎的活检和病理需要知道些什么?

IF 5 2区医学

Current Rheumatology Reports Pub Date : 2022-09-01 Epub Date: 2022-07-27 DOI: 10.1007/s11926-022-01082-6

Chiara Marvisi, Francesco Muratore, Chiara Cabassi, Elena Galli, Luigi Boiardi, Simonetta Piana, Maria Cecilia Mengoli, Carlo Salvarani, Alberto Cavazza

引用次数: 2

Deep Insight into the Role of MIF in Spondyloarthritis. 深入了解MIF在脊椎关节炎中的作用。

IF 5 2区医学

Current Rheumatology Reports Pub Date : 2022-09-01 Epub Date: 2022-07-09 DOI: 10.1007/s11926-022-01081-7

Brian Wu, Akihiro Nakamura

{"title":"Deep Insight into the Role of MIF in Spondyloarthritis.","authors":"Brian Wu, Akihiro Nakamura","doi":"10.1007/s11926-022-01081-7","DOIUrl":"https://doi.org/10.1007/s11926-022-01081-7","url":null,"abstract":"Purpose of review: Pathological roles of macrophage migration inhibitory factor (MIF) have recently been demonstrated in spondyloarthritis (SpA) preclinical models, identifying MIF as a new treatment target for SpA. However, the specific contribution of MIF and therapeutic potential of MIF-targeted therapies to various tissue types affected by SpA are not well delineated.Recent findings: MIF and its cognate receptor CD74 are extensively involved in the pathogenesis of SpA including inflammation in the spine, joint, eyes, skin, and gut. The majority of the current evidence has consistently shown that MIF drives the inflammation in these distinct anatomical sites. In preclinical models, genetic deletion or blockade of MIF reduces the severity of inflammation. Although MIF is generally an upstream cytokine which regulates downstream effector cytokines, MIF also intensifies type 3 immunity by promoting helper T 17 (Th17) plasticity. MIF- or CD74-targeted therapies have also reported to be well tolerated in clinical trials for other diseases. Recent findings suggest that MIF-CD74 axis is a new therapeutic target for SpA to improve various clinical features. Clinical trials for MIF- or CD74-targeted therapies for SpA patients are warranted.","PeriodicalId":10761,"journal":{"name":"Current Rheumatology Reports","volume":"24 9","pages":"269-278"},"PeriodicalIF":5.0,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40487417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1